TÁC DỤNG KHÔNG MONG MUỐN CỦA HOÁ XẠ TRỊ TRÊN UNG THƯ BIỂU MÔ TUYẾN PHỔI GIAI ĐOẠN III BẰNG PHÁC ĐỒ CISPLATIN KẾT HỢP VỚI ETOPOSIDE HOẶC PEMETREXED

Abstract

Concurrent chemoradiotherapy is the primary treatment of inoperable stage III non-small cell lung cancer. For adenocarcinoma, the chemotherapy regimen commonly applied in clinical practice at K Hospital is Etoposide – Cisplatin (EP) or Pemetrexed – Cisplatin (PeC). The objective of the study was to evaluate the side effects of chemotherapy with 2 regimens EP and PeC concurrent with radiotherapy. Subjects and methods: Retrospective study to evaluate side effects of 50 patients treated with Etoposide - Cisplatin (EP) regimen and 31 patients treated with Pemetrexed - Cisplatin (PeC) regimen concurrently with 3D radiation therapy for inoperable stage III adenocarcinoma of lung. Results: The rates of hemoglobinia , neutropenia and thrombocytopenia of EP and PeC regimens were 76%, 84% and 28% and 51.6%, 41.9% and 12.9%, respectively. The rates of hemoglobinia and neutropenia were statistically significantly lower with the PeC regimen than with EP. The rates of pneumonia, esophagitis and dry skin of the two regimens were 22%, 66% and 62% with EP and 16.1%, 48.4% and 45.1% with PeC, respectively. Fatigue rate of 51.6% PeC regimen was significantly lower than that of EP regimen of 84%. Conclusion: The PeC regimen had significantly lower rates of fatigue, hemoglobinia, and neutropenia than the EP regimen.